OmniGuide CEO Scott Flora tells MassDevice.com about his plans to build commercial scale for its BeamPath surgical laser.
MassDevice.com first visited OmniGuide in 2009, when the Cambridge, Mass.-based medical device company was developing the BeamPath laser scalpel, aiming for 2 orders of magnitude more precision than the most precise soft-tissue cutting tool.
Today the company has refined that technology even further and has turned its focus toward ramping up commercialization of the BeamPath device, CEO Scott Flora told us this month.
Since coming aboard last year, Flora has shepherded OmniGuide through a $35 million funding round, built out its commercial and technical team and taken its workforce to 145 employees. When we stopped by, OmniGuide was putting the finishing touches on a major expansion of its facility in the heart of Cambridge's Kendall Square.
The BeamPath technology, developed at the Mass. Institute of Technology by co-founder Yoel Fink, allows photons from a CO2 laser to glide through the hollow core of OmniGuide's proprietary fiber. The hollow core means there's no medium for the laser to travel through, increasing the wavelengths the fibers transfer and creating a more precise beam. At a mere tens of microns wide, the beam is able to pass through flexible conduits into previously inaccessible areas of the body.